{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:ct-nct07033585",
  "owner": "cardio",
  "kind": "study",
  "slug": "nct07033585",
  "name": "Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers",
  "aliases": [
    "NCT07033585"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 600 participants.",
  "summary_technical": "Registry record NCT07033585. Randomized; quadruple masking; primary purpose health services research. Start 2026-06-15 (actual); primary completion 2026-10-18 (anticipated). Results not posted.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-10-26",
  "last_evidence_check": null,
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "nct",
      "value": "NCT07033585",
      "normalized_value": "NCT07033585",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "condition-area": [
        "diabetes-and-metabolic-disease"
      ],
      "system": [
        "metabolism"
      ]
    }
  },
  "payload": {
    "design": "Interventional study; randomized; quadruple masking; primary purpose health services research",
    "drug_phase": "2/3",
    "registry_statuses": [
      {
        "status": "ACTIVE_NOT_RECRUITING",
        "snapshot": "cardio:ctgov-nct07033585-2026-08-27"
      }
    ],
    "start_date": {
      "date": "2026-06-15",
      "type": "actual",
      "snapshot": "cardio:ctgov-nct07033585-2026-08-27"
    },
    "primary_completion_date": {
      "date": "2026-10-18",
      "type": "anticipated",
      "snapshot": "cardio:ctgov-nct07033585-2026-08-27"
    },
    "completion_date": {
      "date": "2026-11-28",
      "type": "anticipated",
      "snapshot": "cardio:ctgov-nct07033585-2026-08-27"
    },
    "results_first_posted": null,
    "countries": [
      {
        "code": "US",
        "snapshot": "cardio:ctgov-nct07033585-2026-08-27"
      }
    ],
    "care_setting": null,
    "stopped_early": null,
    "enrollment": [
      {
        "count": 600,
        "basis": "planned",
        "unit": "participants",
        "snapshot": "cardio:ctgov-nct07033585-2026-08-27"
      }
    ],
    "arms": [],
    "findings": [],
    "registry": [
      {
        "label": "Brief title",
        "value": "Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers",
        "locator": "protocolSection.identificationModule.briefTitle"
      },
      {
        "label": "Acronym",
        "value": "GD-T2D",
        "locator": "protocolSection.identificationModule.acronym"
      },
      {
        "label": "Condition",
        "value": "Type 2 Diabetes",
        "locator": "protocolSection.conditionsModule.conditions[0]"
      },
      {
        "label": "Intervention (Drug)",
        "value": "Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes",
        "locator": "protocolSection.armsInterventionsModule.interventions[0].name"
      },
      {
        "label": "Intervention (Drug)",
        "value": "China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes",
        "locator": "protocolSection.armsInterventionsModule.interventions[1].name"
      },
      {
        "label": "Lead sponsor",
        "value": "Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair",
        "locator": "protocolSection.sponsorCollaboratorsModule.leadSponsor.name"
      },
      {
        "label": "Lead sponsor class",
        "value": "INDUSTRY",
        "locator": "protocolSection.sponsorCollaboratorsModule.leadSponsor.class"
      },
      {
        "label": "Collaborator",
        "value": "UnitedHealthcare",
        "locator": "protocolSection.sponsorCollaboratorsModule.collaborators[0].name"
      },
      {
        "label": "Collaborator class",
        "value": "OTHER",
        "locator": "protocolSection.sponsorCollaboratorsModule.collaborators[0].class"
      }
    ]
  },
  "content_digest": "8dfda6747df4bf8ed604bc641169ed20b69d80b022b419298dbe8a0e73e038e7",
  "review": {
    "content_digest": "8dfda6747df4bf8ed604bc641169ed20b69d80b022b419298dbe8a0e73e038e7",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "investigates",
        "label": "Registry condition terms include this condition",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:type-2-diabetes",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ctgov-nct07033585-2026-08-27",
          "locator": "derivedSection.conditionBrowseModule.meshes[0].id"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "studies/nct07033585/",
  "context_path": "api/v1/context/cardio--ct-nct07033585.md"
}
